Brain injury: Current management and investigations

Seminars in Radiation Oncology

Volumn 13, Issue 3, 2003, Pages 309-321

  Sloan, Andrew E ^b   Arnold, Susanne M ^b   St Clair, William H ^b   Regine, William F ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIESTROGEN; ANTIMETABOLITE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CARMOFUR; CARMUSTINE; CISPLATIN; CYTARABINE; DEXAMETHASONE; FLUDARABINE; FLUOROURACIL; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; PACLITAXEL; PROCARBAZINE; TAMOXIFEN; THIOTEPA; VINCRISTINE;

ASEPTIC MENINGITIS; BRAIN DISEASE; BRAIN EDEMA; BRAIN INJURY; BRAIN METASTASIS; BRAIN NECROSIS; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CEREBELLUM DISEASE; CEREBRAL BLINDNESS; COGNITIVE DEFECT; CONFERENCE PAPER; CRANIAL NERVE INJURY; DEMYELINATING DISEASE; HUMAN; HYPERBARIC OXYGEN; NEUROTOXICITY; PARESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RADIATION INJURY; SEIZURE; SPINAL CORD DISEASE; STROKE; VASCULAR DISEASE;

EID: 0042527714     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-4296(03)00030-4     Document Type: Conference Paper

References (123)

1. Golfinos JG, Fitzpatrick BC, Smith LR, et al: Clinical use of a frameless stereotactic arm: Results of 325 cases. J Neurosurg 83:197-205, 1995
2. Sawaya R, Rambo WM, Hammoud MA, et al: Advances in surgery for brain tumors. Neurol Clin 13:757-771, 1995
3. Gumprecht H, Ebel GK, Auer DP, et al: Neuronavigation and functional MRI for surgery in patients with lesion in eloquent brain areas. Minim Invasive Neurosurg 45:151-153, 2002
4. Sawaya RE, Rambo W, Ligon BE, et al: Basic principles of brain tumor surgery in adults, in Black PM, Loeffler .JS (eds): Cancer of the Nervous System. Cambridge, MA, Blackwell Science, 128-139, 1996
5. Zimmermann M, Seifert V, Trantakis C, et al: Open MRI-guided microneurosurgery of intracranial tumor in or near eloquent brain areas. Acta Neurochir (Wien) 143:327-337, 2001
6. Sawaya R, Hammoud M, Schoppa D, et al: Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42:1044-1056, 1998
7. Kaido T, Nakase H, Nagata K, et al: Intermittent isometric exposure prevents brain retraction injury under venous circulatory impairment. Neurol Res 23:739-744, 2001
8. May M, Sobol SM, Mester SJ: Hypoglossal-facial nerve interpositional-jump graft for facial reanimation with tongue atrophy. Otolaryngol Head Neck Surg 104:818-825, 1991
9. Ciric IS, Rosenblat S: Supatentorial craniotomies, in Apuzzo MLJ (ed): Brain Surgery: Complication Avoidance and Management. New York, Churchill Livingstone, 1993, pp 51-70
10. Stromblad LG, Anderson H, Malmstrom P, et al: Reoperation for malignant astrocytomas: personal experience and a review of the literature. Br J Neurosurg 7:623-633, 1993
11. Hoff JT, McGillicuddy J, Schaberg D: Infections: Prevention and management, in Wirth FP, Ratcheson RA (eds): Neurosurgical Critical Care. Baltimore, MD, Williams & Wilkins, 1987, p 151
12. Yogev R: Cerebrospinal fluid inspectors: A personal view. Pediatr Infect Dis 4:113-118, 1995
13. Koh MS, Goh KY, Tung MY, et al: Is decompressive craniectomy for acute cerebral infarction of any benefit. Surg Neurol 225-230, 2000
14. Suzuki R, Matsushima Y, Takada Y, et al: Changes in cerebral hemodynamics following encephalo-duro-arterio-synangiosis (EDAS) in young patients with moya-moya disease. Surg Neurol 31:343-349, 1989
15. Katayama Y, Oshima H, Fukaya C, et al: Control of post stroke movement disorders using chronic motor cortex stimulation. Acta Neurochir Suppl 79:89-92, 2002
16. Albin MS, Babinski M, Marron JC, et al: Anesthetic management of posterior fossa surgery in the sitting position. Acta Anaesthiol Scand 20:117-128, 1986
17. Rodas RA, Fenstermaker RA, McKeever PE, et al: Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: A preliminary report. J Neurosurg 89:200-205, 1998
18. Roth NM, Sontag MR, Kiani MF: Early effects of ionizing radiation on the microvascular networks in normal tissue. Radiat Res 151:270-277, 1999
19. Bitzer M, Topka H: Progressive cerebral occlusive disease after radiation therapy. Stroke 26:131-136, 1995
20. Rudoltz MS, Regine WF, Langston JW, et al: Multiple causes of cerebrovascular events in children with tumors of the parasellar region. J Neurooncol 37:251-261, 1998
21. Aoki S, Hayashi N, Abe O, et al: Radiation-induced arteritis: thickened wall with prominent enhancement on cranial MR images - Report of five cases and comparison with 18 cases of moyamoya disease. Radiology 223:683-688, 2002
22. Tom'e WA, Mehta MP, Meeks SL, et al: Fractionated stereotactic radiotherapy: A short review. Technol Can Res Treat 1:153-171, 2002
23. Kramer S: Radiation effect and tolerance of the central nervous system. Front Radiat Ther Oncol 6:332-345, 1972
24. Sheline GE, Wara WM, Smith V: Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 12:1765-1769, 1986
25. Fitzek MM, Thornton AF, Rabinov JD, et al: Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: Results of a phase II prospective trial. J Neurosurg 91:251-260, 1999
26. Burger PC, Mahaley MS, Dudka L, et al: The morphologic effects of radiation administrated therapeutically for intracranial gliomas: A postmortem study of 25 cases. Cancer 44:1256-1272, 1979
27. Kumar AJ, Leeds NE, Fuller GN, et al: Malignant gliomas: MR imaging spectrum of radiation therapy and chemotherapy induced necrosis of the brain after treatment. Radiology 217:377-384, 2000
28. Leung SF, Kreel L, Tsao SY: Asymptomatic temporal lobe injury after radiotherapy for nasopharyngeal carcinoma: Incidence and determinants. Br J Radiol 65:710-714, 1992
29. Lee AWM, Kwong DL, Leung S, et al: Factors affecting risk of symptomatic temporal lobe necrosis: Significance of fractional dose and treatment time. Int J Radiat Oncol Biol Phys 53:75-85, 2002
30. Tsui EYK, Chan JHM, Leung TW, et al: Radionecrosis of the temporal lobe: Dynamic susceptibility contrast MRI. Neuroradiol 42:149-152, 2000
31. Davidson A, Tait D, Payne G, et al: Magnetic resonance spectroscopy in the evaluation of neurotoxicity following cranial irradiation for childhood cancer. Br J Radiol 73:421-424, 2000
32. Langleben DD, Segall GM: PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 41:1861-1867, 2000
33. Delattre JY, Rosenblum MK, Thaler HT, et al: A model of radiation myelopathy in the rat. Pathology, regional capillary permeability changes and treatment with dexamethasone. Brain 111:1319-1336, 1988
34. Lee AW, Ng SH, Ho JH, et al: Clinical diagnosis of late temporal lobe necrosis following radiation therapy for nasopharyngeal carcinoma. Cancer 6:1535-1542, 1988
35. Tada E, Matsumoto K, Kinoshita K, et al: The protective effect of dexamethasone against radiation damage induced by interstitial irradiation in normal monkey brain. Neurosurg 41:209-217, 1997
36. Martins AN, Severance RE, Henry JM, et al: Experimental delayed radiation necrosis of the brain. Part 1: Effect of early dexamethasone treatment. J Neurosurg 51:587-596, 1979
37. Gutin PH. Treatment of radiation necrosis of the brain, in Gutin PH, Leibel SA, Sheline GE (eds): Radiation Injury To The Nervous System. Raven Press Inc, 1991, pp 271-282
38. Di Lorenzo N, Nolletti A, Palma L: Late cerebral radio-necrosis. Surg Neurol 10:281-289, 1978
39. Chuba RJ, Aronin P, Bhambhani K, et al: Hyperbaric oxygen therapy for radiation-induced brain injury in children. Cancer 80:2005-2012, 1997
40. Leber KA, Eder HG, Kovac H, et al: Treatment of cerebral radionecrosis by hyperbaric oxygen therapy. Stereotact Funct Neurosurg 70:229-236, 1997
41. Ashamalla HL, Thom SR, Goldwein JW, et al: Hyperbaric oxygen therapy for the treatment of radiation-induced sequalae in children. The University of Pennsylvania experience. Cancer 77:2407-2412, 1996
42. Oldfield EH, Friedman R, Kinsella T, et al: Reduction in radiation-induced brain injury by use of pentobarbital or lidocaine protection. J Neurosurg 72:737-744, 1990
43. Denekamp J, Terry NHA, Sheldon PW, et al: The effect of pentoldarbital anesthesia on the radiosensitivity of four mouse tumors. Int J Radiat Biol 35:277-280, 1979
44. Nieder C, Leicht A, Motaref B, et al: Late radiation toxicity after whole-brain radiotherapy. Am J Clin Oncol 22:573-579, 1999
45. Ris MD, Packer R, Goldwein J, et al: Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma. J Clin Oncol 19:3470-3476, 2001
46. Silber JH, Radcliffe J, Peckham V, et al: Whole-brain irradiation and decline in intelligence: The influence of dose and age on IQ score. J Clin Oncol 10:1390-1396, 1992
47. Hochberg F, Slotnick B: Neuropsychologic impairment in astrocytoma survivors. Neurology 30:172-177, 1980
48. Duffner PK, Horowitz ME, Krischner JP, et al: Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328:1725-1731, 1993
49. Hoppe-Hirsch E, Renier S, Lellouch-Tubiana A, et al: Medulloblastoma in childhood: Progressive intellectual deterioration. Childs Nerv Syst 6:60-65, 1990
50. Walter AW, Mulhern RK, Gajjar A, et al: Neurodevelopmental outcome of young children with medulloblastoma at St. Jude's Children's Research Hospital. J Clin Oncol 17:3720-3728, 1999
51. Packer RJ, Sposto R, Atkins TE, et al: Quality of life in children with primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa. Pediatric Neurosci 13:169-175, 1987
52. Mulhern RK, Kovnar E, Langston J, et al: Long-term survivors of leukemia treated in infancy: Factors associated with neuropsychologic status. J Clin Oncol 10:1095-1102, 1992
53. Palmer S, Goloubeva O, Reddick WE, et al: Patterns of intellectual development among survivors of pediatric medulloblastoma: A longitudinal analysis. J Clin Oncol 19:2302-2308, 2001
54. Merchant TE, Kiehna EN, Miles MA, et al: Acute effects of irradiation on cognition: Changes in attention on a computerized continuous performance test during radiotherapy in pediatric patients with localized primary brain tumors. Int J Radiat Oncol Biol Phys 53:1271-1278, 2002
55. Laukkanen E, Klonoff H, Allan B, et al: The role of prophylactic brain irradiation in limited stage small cell lung cancer: Clinical, neuropsychologic and CT sequelae. Int J Radiat Oncol Biol Phys 14:1109-1117, 1988
56. Twijnstra A, Boon PJ, Lormans ACM, et al: Neurotoxicity of prophylactic cranial irradiation in patients with small cell carcinoma of the lung. Eur J Cancer Clin Oncol 23:983-986, 1987
57. DeAngelis LM, Delattre JY, Posner JB, et al: Radiation-induced dementia in patients cured of brain metastasis. Neurology 39:789-796, 1989
58. Surma-aho O, Niemela M, Vikki P, et al: Adverse long-term effects of brain radiotherapy in adult low-grade gliomas patients. Neurology 56:1285-1290, 2001
59. Taylor BV, Buckner JC, Cascino TL, et al: Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. J Clin Oncol 16:2195-2201, 1998
60. Regine WF, Scott C, Murray K, et al: Neurocognitive outcome in brain metastasis patients treated with accelerated fractionation vs. accelerated hyperfractioned radiotherapy: An analysis from radiation therapy oncology group study 91-04. Int J Radiat Oncol Biol Phys 51:711-717, 2001
61. Highfield DA, Hu D, Amsel A: Alleviation of x-irradiation-based deficit in memory-based learning by D-amphetamine: Suggestions for attention deficit-hyperactivity disorder. Proc Natl Acad Sci U S A 95:5785-5788, 1998
62. Meyers CA, Weitzner MA, Valentine AD, et al: Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 16:2522-2527, 1998
63. Cheung M, Chan AS, Law SC, et al: Cognitive function of patients with nasopharyngeal carcinoma with and without temporal lobe radionecrosis. Arch Neurol 57:1347-1352, 2000
64. Parsons JT, Boya FJ, Fitzgerald CR, et al: Radiation optic neuropathy after megavoltage external-beam irradiation: Analysis of time-dose factors. Int J Radiat Oncol Biol Phys 30:755-763, 1994
65. Tishler RB, Loeffler JS, Lunsford LD, et al: Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys 27:215-221, 1993
66. Kwong DL, Wei WI, Sham JST, et al: Sensorineural hearing loss in patient treated for nasopharyngeal carcinoma: A prospective study of the effect of radiation and cisplatin treatment. Int J Radiat Oncol Biol Phys 36:281-289, 1996
67. Leach W: Irradiation of the ear. J Laryngol 79:870-880, 1965
68. Johannesen TB, Rusmussen K, Winther FO, et al: Late radiation effects on hearing, vestibular function and taste in brain tumor patients. Int J Radiat Oncol Biol Phys 53:86-90, 2002
69. Kiu MC, Liaw CC, Yang TS, et al: Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma. Anticancer Drugs 5:480-482, 1994
70. Hitchins RN, Thomson DB: Encephalopathy following cisplatin, bleomycin and vinblastine therapy for nonseminomatous germ cell tumour of testis. Aust N Z J Med 18:67-68, 1988
71. Weiden PL, Wright SE: Vincristine neurotoxicity. N Engl J Med 286:1369-1370, 1972
72. Hook CC, Kimmel DW, Kvols LK, et al: Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 31:262-267, 1992
73. Baker RJ, Royer GL, Weiss RB: Cytarabine and neurologic toxicity. J Clin Oncol 9:679-693, 1991
74. Weiss HD, Walker MD, Wiernik PH: Neurotoxicity of commonly used antineoplastic agents. N Engl J Med 291:127-133, 1974
75. Burger PC, Kamenar E, Schold SC, et al: Encephalomyelopathy following high-dose BCNU therapy. Cancer 48:1318-1327, 1981
76. Lewis LD, Meanwell CA: Ifosfamide pharmacokinetics and neurotoxicity. Lancet 335:175-176, 1990
77. Perry JR, Warner E: Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology 46:1596-1599, 1996
78. Lazarus HM, Reed MD, Spitzer TR, et al: High close IV thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 71:689-695, 1987
79. Keime-Guibert F, Napolitano M, Delattre JY: Neurological complications of radiotherapy and chemotherapy. J Neurol 245:695-708, 1998
80. Zulian GB, Tullen E, Maton B: Methylene blue for ifosfamide-associated encephalopathy. N Engl J Med 332:1239-1240, 1995
81. Marcus RE, Goldman JM: Convulsions due to high-dose busulphan. Lancet 2:1463, 1984
82. Martell RW, Sher C, Jacobs P, et al: High-dose busulfan and myoclonic epilepsy. Ann Intern Med 106:173, 1987
83. Bellin SL, Selim M: Cisplatin-induced hypomagnesemia with seizures: A case report and review of the literature. Gynecol Oncol 30:104-113, 1988
84. Ritch PS: Cis-dichlorodiammineplatinum II-induced syndrome of inappropriate secretion of antidiuretic hormone. Cancer 61:448-450, 1988
85. Chun HG, Leyland-Jones BR, Caryk SM, et al: Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 70:1225-1228, 1986
86. Gonzalez H, Bolgert F, Camporo P, et al: Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). Hematol Cell Ther 41:183-186, 1999
87. Lazarus HM, Herzig RH, Herzig GP, et al: Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 48:2577-82, 1981
88. Herzig RH, Hines JD, Herzig GP, et al: Cerebellar toxicity with high dose cytarabine arabinoside. J Clin Oncol 5:927-932, 1987
89. Graves T, Hooks MA: Drug-induced toxicities associated with high-dose cytosine arabinoside infusions. Pharmacotherapy 9:23-28, 1989
90. Barnett MJ, Ganesan TS, Waxman JH, et al: Neurotoxicity of high-dose cytosine arabinoside. Prog Exp Tumor Res 29:177-182, 1985
91. Tuchman M, Stoeckeler JS, Kiang DT, et al: Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313:245-249, 1985
92. Stephan F, Etienne MC, Wallays C, et al: Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am J Med 99:685-688, 1985
93. Takimoto CH, Lu ZH, Zhang R, et al: Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihxdropyrimidine dehydrogenase deficiency. Clin Cancer Res 2:477-481, 1996
94. Pirzada NA, Ali II, Dafer RM: Fluorouracil-induced neurotoxicity. Ann Pharmacother 34:35-38, 2000
95. Walker RW, Allen JC, Rosen G, et al: Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 4:1847-1850, 1986
96. Walker RW, Cairncross JG, Posner JB: Cerebral herniation in patients receiving cisplatin. J Neurooncol 6:61-65, 1988
97. Hughes PJ, Lane RJM: Acute cerebral oedema induced by methotrexate. BMJ 298:1315, 1989
98. van Gelder T, Geurs T, Kho GS., et alCortical blindness and seizures following cisplatin treatment. Both of epileptic origin. Eur J Cancer 29:1497, 1993(abstr)
99. Berman IJ, Mann MP: Seizures and transient cortical blindness associated with cis-platinum II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer 45:764-766, 1980
100. O'Brien ME, Tonge K, Blake P, et al: Blindness associated with high-dose carboplatin. Lancet 339:558, 1992
101. Troy L, McFarland K, Littman-Power S, et al: Cisplatin-based therapy: A neurological and neuropsychological review. Psychooncology 9:29-39, 2000
102. Butler RW, Hill JM, Steinherz PG, et al: Neuropsychological effects of cranial irradiation, intrathecal methotrexate and systemic methotrexate in childhood cancer. J Clin Oncol 12:2621-2629, 1994
103. Ahles TA, Saykin A: Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest 19:812-820, 2001
104. Schlegel U, Pels H, Oehring R, et al: Neurologic sequelae of treatment of primary CNS lymphomas. J Neurooncol 43:277-286, 1999
105. Weitzner MA, Meyers CA: Cognitive functioning and quality of life in malignant glioma patients: A review of the literature. Psychooncology 6:169-177, 1997
106. Regine WF, Huhn JL, Patchell RA, et al: Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: Results and implications. Int J Radiat Oncol Biol Phys 52:333-338, 2002
107. Langer T, Martus P, Ottensmeier H, et al: CNS late-effects after ALL therapy in childhood. Part III: Neuropsychological performance in long-term survivors of childhood ALL: Impairments of concentration, attention, and memory. Med Pediatr Oncol 38:320-328, 2002
108. Schlegel U, Pels H, Oehring R, et al: Neurologic sequellae of treatment of primary CNS lymphomas. J Neurooncol 43:277-286, 1999
109. Tuxen MK, Hansen SW: Neurotoxicity secondary to antineoplastic agents. Cancer Treat Rev 20:191-214, 1994
110. Blay JY, Contory T, Chevereau C, et al: High dose methotrexate for the treatment of primary central nervous system lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16:864-871, 1998
111. Saleh MN, Christian ES, Diamond BR: Intrathecal cytosine arabinoside-induced acute, rapidly reversible paralysis. Am J Med 86:729-730, 1989
112. Meggs J, Hoffman RS: Fatality resulting from intraventricular vincristine administration. J Toxicol Clin Toxicol 36:243-246, 1998
113. Watterson J, Toogood I, Nieder M, et al: Excessive spinal cord toxicity from intensive central nervous system directed therapies. Cancer 74:3034-3041, 1994
114. Glantz MJ, Hall WA, Cole BF, et al: Diagnosis, management and survival of patients with leptomeningeal cancer based on cerebrospinal fluid flow status. Cancer 75:2919-2931, 1995
115. Mason WP, Yeh SD, DeAngeleis LM: Indium diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 50:4388-4444, 1998
116. Spiefel RJ, Cooper PR, Blum RH, et al: Treatment of massive intrathecal methotrexate overdose by ventriculolumbar perfusion. N Engl J Med 331:386-388, 1984
117. Jakobson AM, Kreuger A, Mortimer O, et al: Cerebrospinal fluid exchange after intrathecal methotrexate overdose - A report of two cases. Acta Pediatr 81:359-361, 1992
118. O'Marcaigh AS, Johnson CM, Smithson WA, et al: Successful treatment of intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidease G2. Mayo Clin Proc 71:161-165, 1991
119. Jackson DV, Wells HB, Atkins JN, et al: Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 84:1016-1022, 1988
120. Jardine LF, Ingram LC, Bleyer WA: Intrathecal leucovorin after intrathecal methotrexate overdoseage. J Pediatr Hematol Oncol 18:302-304, 1996
121. Brem H, Ewend MG, Piantadosi S, et al: The safety of interstitial chemotherapy with BCNU loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol 26:111-123, 1995
122. Brem H, Gabikian P: Biodegradable polymer implants to treat brain tumors, J Control Release 74:63-67, 2001
123. Nakagawa H, Maeda N, Tsuzuki T, et al: Intracavitary chemotherapy with 5-fluoro-2′-deoxyuridine (FdUrd) in malignant brain tumors. Jpn J Clin Oncol 31:251-258, 2001